Thomas Fremming Dejgaard
Thomas Fremming Dejgaard
Steno Diabetes Center Copenhagen
Verified email at
Cited by
Cited by
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo …
TF Dejgaard, CS Frandsen, TS Hansen, T Almdal, S Urhammer, ...
The lancet Diabetes & endocrinology 4 (3), 221-232, 2016
Changes in insulin sensitivity precede changes in body composition during 14 days of step reduction combined with overfeeding in healthy young men
SH Knudsen, LS Hansen, M Pedersen, T Dejgaard, J Hansen, GV Hall, ...
Journal of applied physiology 113 (1), 7-15, 2012
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
CS Frandsen, TF Dejgaard, S Madsbad
The Lancet Diabetes & Endocrinology 4 (9), 766-780, 2016
Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind …
CS Frandsen, TF Dejgaard, JJ Holst, HU Andersen, B Thorsteinsson, ...
Diabetes Care 38 (12), 2250-2257, 2015
Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy
T Hvid, K Winding, A Rinnov, T Dejgaard, C Thomsen, P Iversen, ...
Endocrine-related cancer 20 (5), 621-632, 2013
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
NJ Johansen, TF Dejgaard, A Lund, C Schlüntz, CS Frandsen, JL Forman, ...
The Lancet Diabetes & Endocrinology 8 (4), 313-324, 2020
Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo …
CS Frandsen, TF Dejgaard, HU Andersen, JJ Holst, B Hartmann, ...
Diabetes, Obesity and Metabolism 19 (6), 773-782, 2017
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised …
K Færch, MB Blond, L Bruhn, H Amadid, D Vistisen, KKB Clemmensen, ...
Diabetologia 64, 42-55, 2021
Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: the lira pump trial—a randomized, double …
TF Dejgaard, S Schmidt, CS Frandsen, D Vistisen, S Madsbad, ...
Diabetes, Obesity and Metabolism 22 (4), 492-500, 2020
Emerging drugs for the treatment of obesity
C Martinussen, KN Bojsen-Moller, MS Svane, TF Dejgaard, S Madsbad
Expert opinion on emerging drugs 22 (1), 87-99, 2017
Duration and complications of diabetes mellitus and the associated risk of infective endocarditis
L Østergaard, UM Mogensen, JS Bundgaard, A Dahl, A Wang, ...
International Journal of Cardiology 278, 280-284, 2019
Liraglutide for treating type 1 diabetes
TF Dejgaard, CS Frandsen, JJ Holst, S Madsbad
Expert Opinion on Biological Therapy 16 (4), 579-590, 2016
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
SM Heimbürger, A Brønden, NJ Johansen, TF Dejgaard, T Vilsbøll, ...
Expert Opinion on Pharmacotherapy 20 (5), 501-510, 2019
Non-insulin pharmacological therapies for treating type 1 diabetes
CS Frandsen, TF Dejgaard, S Madsbad, JJ Holst
Expert Opinion on Pharmacotherapy 19 (9), 947-960, 2018
Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a …
TF Dejgaard, FK Knop, L Tarnow, CS Frandsen, TS Hansen, T Almdal, ...
BMJ open 5 (4), e007791, 2015
Continuous glucose monitoring adds information beyond HbA1c in well-controlled diabetes patients with early cardiovascular autonomic neuropathy
J Fleischer, E Laugesen, SL Cichosz, P Hoeyem, TF Dejgaard, ...
Journal of Diabetes and its Complications 31 (9), 1389-1393, 2017
Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes
L Østergaard, CS Frandsen, TF Dejgaard, S Madsbad
Expert Review of Clinical Pharmacology 10 (6), 621-632, 2017
Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes
TF Dejgaard, NB Johansen, CS Frandsen, A Asmar, L Tarnow, FK Knop, ...
Diabetes, Obesity and Metabolism 19 (5), 734-738, 2017
Glycemic control and variability of diabetes secondary to total pancreatectomy assessed by continuous glucose monitoring
CTB Juel, TF Dejgaard, CP Hansen, JH Storkholm, T Vilsbøll, A Lund, ...
The Journal of Clinical Endocrinology & Metabolism 106 (1), 168-173, 2021
59-OR: Liraglutide Preserved Insulin Secretion in Adults with Newly Diagnosed Type 1 Diabetes: The NewLira Trial
TF Dejgaard, CS Frandsen, URD Kielgast, HU Andersen, B Thorsteinsson, ...
Diabetes 68 (Supplement_1), 2019
The system can't perform the operation now. Try again later.
Articles 1–20